- KAI licenses cardiovascular candidate to Sankyo; deal ended
- KAI closes $17mm Series A round; gets another $11mm
- Sankyo to buy Daiichi for $7.7bn
- Series B brings in $35mm for KAI Pharmaceuticals
- BMS gets Phase II heart attack candidate from KAI
- AstraZeneca takes on Targacept's cognitive disorder candidate; deal ends
- GSK and Synta in cancer co-development deal; ended
- Synta licenses anti-inflammatory candidates to Roche; terminated
- Infinity, MedImmune, AZ restructure Hedgehog deal
- AstraZeneca buys MedImmune for $15.6bn
- Purdue, Mundipharma, Infinity in major oncology/pain deal; relationship ends
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. firstname.lastname@example.org.
All fields are required.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.